Genmab (ADR) (GMAB)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
$35.22
After hours+0.01 (+0.03%)
At close$35.21(+1.50%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,712 | 4,678 | 603 | 779 | 5,540 | 6,441 | 105 | 925 | 1,022 | 1,055 | 899 | 1,155 |
| Cost of revenue | 79 | 126 | 27 | 28 | 273 | 337 | 6 | 57 | 58 | 81 | 65 | 84 |
| Gross profit | 4,633 | 4,552 | 576 | 751 | 5,267 | 6,104 | 99 | 868 | 964 | 974 | 834 | 1,071 |
| 2,948 | 2,882 | 460 | 515 | 3,165 | 3,944 | 71 | 508 | 505 | 732 | 608 | 664 | |
| Research & development | 2,088 | 1,948 | 335 | 361 | 2,283 | 2,664 | 53 | 364 | 357 | 524 | 442 | 459 |
| Selling, general & administrative | 860 | 934 | 125 | 129 | 865 | 1,249 | 19 | 144 | 148 | 207 | 167 | 205 |
| Other expenses | 0 | 0 | 0 | 25 | 17 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 1,685 | 1,670 | 116 | 236 | 2,102 | 2,160 | 28 | 360 | 459 | 242 | 226 | 407 |
| 985 | −744 | 133 | 71 | −383 | 1,442 | 8 | 63 | 23 | −187 | −152 | −112 | |
| Interest income | 243 | 295 | 46 | 292 | 162 | 224 | 5 | 25 | 32 | 48 | 14 | 36 |
| Interest expense | 8 | 6 | 4 | 19 | 18 | 54 | 1 | 9 | 3 | 44 | 112 | 110 |
| Other non-operating income | −994 | 738 | −137 | −74 | −17 | −107 | −9 | −72 | −26 | 144 | 39 | 2 |
| Income before tax | 2,670 | 926 | 249 | 307 | 1,719 | 3,602 | 36 | 423 | 482 | 55 | 74 | 295 |
| Income tax expense | 566 | 286 | 57 | 104 | 453 | −243 | 7 | 87 | 81 | 24 | 21 | −8 |
| Net income from continuing operations | 2,104 | 640 | 192 | 203 | 1,266 | 3,845 | 29 | 336 | 401 | 31 | 53 | 303 |
| Net income | 2,104 | 640 | 192 | 203 | 1,266 | 3,845 | 29 | 336 | 401 | 31 | 53 | 303 |
| EPS, basic | $3.26 | $0.98 | $2.03 | $0.32 | $1.95 | $5.99 | $0.05 | $0.54 | $0.65 | $0.05 | $0.09 | $0.49 |
| EPS, diluted | $3.23 | $0.97 | $2.02 | $0.31 | $1.95 | $5.99 | $0.05 | $0.54 | $0.65 | $0.05 | $0.08 | $0.49 |
| Weighted average shares, basic | 653 | 653 | 653 | 649 | 649 | 642 | 637 | 618 | 616 | 616 | 614 | 613 |
| Weighted average shares, diluted | 659 | 658 | 657 | 649 | 649 | 642 | 639 | 620 | 621 | 673 | 639 | 617 |
| EBITDA | 2,764 | 992 | 266 | 324 | 2,204 | 2,355 | 39 | 448 | 503 | 99 | 187 | 431 |
| Depreciation & amortization | 85 | 60 | 13 | 14 | 85 | 88 | 2 | 16 | 18 | 0 | 0 | 26 |
| EBIT | 2,679 | 932 | 253 | 310 | 2,119 | 2,267 | 37 | 432 | 485 | 99 | 187 | 405 |